About Nuage Therapeutics
Nuage Therapeutics is a Healthcare company based in Barcelona (Spain) founded in 2021 by Judit Anido Folgueira, Mateusz Biesaga, Denes Hnisz, and Xavier Salvatella. Drugs are developed for intrinsically disordered protein targets. Nuage Therapeutics has raised $13.1 million across 1 funding round from investors including Sofinnova Partners and Asabys Partners. Its chief executive, as recorded, is Judit Anido Folgueira. Nuage Therapeutics offers products and services including Disordered Protein Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Prostate Cancer.
Company details
Nuage Therapeutics was founded in 2021 in Barcelona, Spain, within the biotechnology sector. Drug screening assays are developed to address intrinsically disordered proteins involved in biomolecular condensation. Treatments for castration-resistant prostate cancer are targeted through these efforts. Operations focus on innovative drug discovery methods, with a team of co-founders leading research and development activities in Europe.
- Headquarters Barcelona, Spain
- Founders Judit Anido Folgueira, Mateusz Biesaga, Denes Hnisz, Xavier Salvatella
- SectorsHealthcare
- Website nuagetx.com
- Social LinkedIn
- Total Equity Funding$13.1M (USD)
in 1 rounds
- Latest Funding Round$13.1M (USD), Seed
Jun 2023
- InvestorsSofinnova Partners
& 1 more
Products & Services of Nuage Therapeutics
Nuage Therapeutics offers a comprehensive portfolio of products and services, including Disordered Protein Therapies.
Innovative treatments targeting disordered proteins for cancer and diseases
Funding Insights of Nuage Therapeutics
Nuage Therapeutics has successfully raised a total of $13.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $13.1 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.1M
- Total Rounds 1
- Last Round Seed — $13.1M
- First Round $13.1M
(Jun 2023)
- Investors Count 2
All 1 funding rounds of Nuage Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $13.1M | Seed | – | Sofinnova Partners, Asabys Partners | – |
2 investors in total: 2 institutional.
Investors in Nuage Therapeutics
Nuage Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sofinnova Partners and Asabys Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
| asabys.com |
Investor details for Nuage Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nuage Therapeutics
4 people are tracked at Nuage Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
Judit Anido Folgueira | Co-Founder & CEO | Leadership |
Mateusz Biesaga | Co-Founder | Leadership |
Denes Hnisz | Co-Founder | Leadership |
Xavier Salvatella | Co-Founder | Leadership |
Complete people profiles for Nuage Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nuage Therapeutics
2 dated milestones of Nuage Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Nuage Therapeutics is founded.
- Funding First funding round of $13.1M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuage Therapeutics
Complete news archive for Nuage Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuage Therapeutics
Nuage Therapeutics was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Nuage Therapeutics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Judit Anido Folgueira is the CEO of Nuage Therapeutics, as recorded in our data. They have also founded this company.
Nuage Therapeutics is a funded company, having raised a total of $13.1M across 1 funding round to date. The company's 1st funding round was a Seed of $13.1M, raised on Jun 2023.
Nuage Therapeutics was founded in 2021 in Barcelona, Spain, within the biotechnology sector. Drug screening assays are developed to address intrinsically disordered proteins involved in biomolecular condensation. Treatments for castration-resistant prostate cancer are targeted through these efforts. Operations focus on innovative drug discovery methods, with a team of co-founders leading research and development activities in Europe.
Nuage Therapeutics offers Disordered Protein Therapies.
Nuage Therapeutics has 2 investors. Key investors include Sofinnova Partners, and Asabys Partners.